Transl Clin Pharmacol.  2014 Jun;22(1):19-21.

Pregnane X Receptor agonist Increases the Expression Levels of the Plasma Membrane Monoamine Transporter

Affiliations
  • 1Department of Pharmacology, Yonsei University College of Medicine, Seoul 120-752, Korea.
  • 2Clinical Trial Center, Yonsei University, Seoul 120-752, Korea.
  • 3Department of Pediatrics, Yonsei University College of Medicine, Seoul 120-752, Korea. minspark@yuhs.ac
  • 4Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam 463-707, Korea. jychung@snubh.org

Abstract

We evaluated the effect of the pregnane X receptor agonist, pregnenolone 16 alpha-carbonitrile (PCN) on the expression levels of plasma monoamine transporter (PMAT) in the intestine. Male C57/BL6 mice were divided into two 2 groups: mice in the PCN group (n=3) were administered PCN once a day for 4 days, while those in the control group (n=3) received the same volume of vehicle once a day for 4 days. After the mice were killed 24 h after administration of the last dose of PCN or vehicle, and the expression levels of PMAT in the intestine tissues were isolated and measured the expression level of PMAT using immunohistochemical and western blotting analyses. The expression level of PMAT expression levels in the small intestine increased after PCN treatment. These results suggest that the induction of PMAT may play a clinically significant role by increasing intestinal absorption of PMAT substrates such as metformin.

Keyword

PXR; PMAT; PCN; Expression

MeSH Terms

Animals
Blotting, Western
Cell Membrane*
Humans
Intestinal Absorption
Intestine, Small
Intestines
Male
Metformin
Mice
Plasma
Pregnenolone Carbonitrile
Metformin
Pregnenolone Carbonitrile

Figure

  • Figure 1. Effect of pregnenolone 16 alpha-carbonitrile (PCN) on PMAT expression in C57/BL6 mice. Representative immunohistochemical images for PMAT staining in the small intestine in the control (left) and PCN (right) animals.

  • Figure 2. The effect of PCN on PMAT expression in the liver and small intestine as assessed using western blotting analyses (samples were pooled).


Reference

References

1. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007; 74:359–371.
Article
2. Sugawara-Yokoo M, Urakami Y, Koyama H, Fujikura K, Masuda S, Saito H, et al. Differential localization of organic cation transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney proximal tubules. Histochem Cell Biol. 2000; 114:175–180.
Article
3. Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem. 2004; 279:50042–5049.
Article
4. Ho HT, Pan Y, Cui Z, Duan H, Swaan PW, Wang J. Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter. J Pharmacol Exp Ther. 2011; 339:376–385.
Article
5. Engel K, Wang J. Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol. 2005; 68:1397–1407.
Article
6. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007; 35:1956–1962.
Article
7. Xia L, Zhou M, Kalhorn TF, Ho HT, Wang J. Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleo-side nephrotoxicity. Am J Physiol Renal Physiol. 2009; 296:F1307–F1313.
Article
8. Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, et al. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther. 2011; 89:416–421.
Article
9. Lickteig AJ, Cheng X, Augustine LM, Klaassen CD, Cherrington NJ. Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci. 2008; 83:59–64.
Article
10. Maeda T, Oyabu M, Yotsumoto T, Higashi R, Nagata K, Yamazoe Y, et al. Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats. Drug Metab Dispos. 2007; 35:1580–1586.
Article
11. Kim W, Seong J, An JH, Oh HJ. Enhancement of tumor radioresponse by wortmannin in C3H/HeJ hepatocarcinoma. J Radiat Res. 2007; 48:187–195.
Article
12. Seong J, Oh HJ, Kim J, An JH, Kim W. Identification of proteins that regulate radiation-induced apoptosis in murine tumors with wild type p 53. J Radiat Res. 2007; 48:435–441.
13. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009; 50:1227–1240.
Article
14. Nie W, Sweetser S, Rinella M, Green RM. Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-alpha and -gamma. Am J Physiol Gastrointest Liver Physiol. 2005; 288:G207–G212.
15. Xu S, Sun AQ, Suchy FJ. A novel RARα/CAR-mediated mechanism for regulation of human organic solute transporter-β gene expression. Am J Physiol Gastrointest Liver Physiol. 2014; 306:G154–162.
Article
Full Text Links
  • TCP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr